Skip to main content
Premium Trial:

Request an Annual Quote

Signal Extends Gene Array Testing Services Agreements with UAMS

NEW YORK (GenomeWeb) – Signal Genetics said in a regulatory document on Wednesday that it has reached agreements to exclusively provide gene array clinical genetic testing services to the University of Arkansas for Medical Sciences.

The New York City-based firm signed a reference laboratory services agreement with the board of trustees of the University of Arkansas on behalf of UAMS, Signal said in a document filed with the US Securities and Exchange Commission. It also reached a reference laboratory services agreement for research specimens to be the exclusive provider of gene array clinical genetic testing services for research purposes to UAMS.

Both agreements were entered into on Sept. 19 and remain in effect until Sept. 19, 2017. They can be renewed after the end of the initial term by Signal and UAMS for additional 12-month terms. Financial and other terms of the agreements were not disclosed.

The deals renew and extend Signal's current reference laboratory services agreement and reference laboratory services agreement for research specimens with UAMS, dated March 21, 2011, Signal said.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.